

**POLYCLONAL ANTIBODY TO
HUMAN BRAIN FATTY ACID BINDING PROTEIN
(B-FABP, FABP7)**



| Catalog n° | HP9029 (lot number and expiry date are indicated on the label) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|------------------------------|---|---|----|----|----|----|----|----|----|---|---|-----|--|--|--|---|--|--|--|---|----|--|--|--|--|--|--|--|--|------|---|---|---|--|---|---|---|--|
| Description | The polyclonal antibody recognizes human brain fatty acid binding protein (B-FABP) of both natural and recombinant origin. The B-FABP protein is derived from the human <i>FABP7</i> gene. FABPs are small intracellular proteins (~13-14 kDa) with a high degree of tissue specificity that bind long chain fatty acids. They are abundantly present in various cell types and play an important role in the intracellular utilization of fatty acids, transport and metabolism. There are at least nine distinct types of FABP, each showing a specific pattern of tissue expression. Due to its small size, FABP leaks rapidly out of ischemically damaged necrotic cells leading to a rise in serum levels. Ischemically damaged tissues are characterized histologically by absence (or low presence) of FABP facilitating recognition of such areas. B-FABP is localized in the brain and other neural tissues. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Aliases | FABP7, Brain lipid-binding protein, Mammary-derived growth inhibitor related | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Species | Rabbit IgG | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cross reactivity | Cross reactant | Reactivity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Human H-FABP | Average | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Formulation | 1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Application | <table border="1"> <thead> <tr> <th></th> <th>F</th> <th>FC</th> <th>FS</th> <th>IA</th> <th>IF</th> <th>IP</th> <th>P</th> <th>W</th> </tr> </thead> <tbody> <tr> <td>Yes</td> <td></td> <td></td> <td></td> <td>•</td> <td></td> <td></td> <td></td> <td>•</td> </tr> <tr> <td>No</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>N.D.</td> <td>•</td> <td>•</td> <td>•</td> <td></td> <td>•</td> <td>•</td> <td>•</td> <td></td> </tr> </tbody> </table> | | | F | FC | FS | IA | IF | IP | P | W | Yes | | | | • | | | | • | No | | | | | | | | | N.D. | • | • | • | | • | • | • | |
| | F | FC | FS | IA | IF | IP | P | W | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Yes | | | | • | | | | • | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| No | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| N.D. | • | • | • | | • | • | • | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | <small>N.D. = Not Determined; F = Frozen sections; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IF = Immuno Fluorescence; IP = Immuno Precipitation; P = Paraffin sections; W = Western blot</small> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Use | For Western blotting, dilution to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Storage and stability | Product should be stored at 4°C. Under recommended storage conditions, product is stable for one year. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Precautions | For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use or derivation of this product. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| References | <ol style="list-style-type: none"> 1. Veerkamp, J et al; Cytoplasmic fatty acid-binding proteins: their structure and genes. Prog Lipid Res 1995, 34: 17 2. Veerkamp, J et al; Stuctural and functional studies on different human FABP types. Mol Cell Biochem 1999, 192: 137 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Also available | HP9020 | Polyclonal antibody against Human I-FABP | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | HP9021 | Polyclonal antibody against Human L-FABP | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | HP9028 | Polyclonal antibody against Human A-FABP | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | HP9030 | Polyclonal antibody against Human E-FABP | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | HP9031 | Polyclonal antibody against Human IL-FABP | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | HP9032 | Polyclonal antibody against Human M-FABP | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |